Followers | 27 |
Posts | 3920 |
Boards Moderated | 0 |
Alias Born | 01/02/2003 |
Monday, May 24, 2021 11:23:51 AM
For me, last week's unbelievably impressive results removed a lot of risk as I believe it demonstrates Proof of Concept. Assuming it shows similar or better results in 2 weeks, followed later this year with Keytruda combo and MD Anderson trials, today's price could be the buy of the decade.
IF, and I say IF, the data demonstrates PoC with the other 2 trials, there is no reason a $5 billion and higher market cap isn't possible and is likely imo. Throw in possible Covid approval and a $5 billion market cap will be small in 6-12 months. I know a lot has to go PDS way, but last week's data was huge. With current share count less than 23 million, dream about what a $5 billion market cap translates to, sounds CRAZY, but it is possible.
Recent PDSB News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 12:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 11:05:43 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 08:39:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:13:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:06:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 12:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 12:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:45:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 12:05:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:16:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:33:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:10:16 PM
- PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 01/22/2024 09:45:19 PM
- PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/04/2023 09:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:02:38 PM
- PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer • GlobeNewswire Inc. • 11/28/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 11:02:46 AM
- PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 12:30:55 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM